🟢 Heron Therapeutics is trading 6.5% up in pre-market after extending Tax Benefit Preservation Plan through 2029

Heron Therapeutics is trading at $0.36, up +6.47% in pre-market after amending its Tax Benefit Preservation Plan.

• The plan is designed to preserve the company’s tax assets by limiting ownership changes.
• The August 13, 2026, amendment extends expiration through August 14, 2029.
• The filing appeared after the August 14 session and is the clearest company-specific overnight catalyst; broader-market strength may also support risk appetite.